Dr. Irina Staatz
Staatz Consulting
Picture: Staatz Consulting
Luncheons
Conference room: Händel-Saal
Why should Regulatory and HTA expectations be aligned early and addressed in parallel during development? How can this dual track approach shape product profiles, de-risk investments, and strengthen partnering prospects?
Furthermore, do Orphan Drugs operate under distinct regulatory frameworks and HTA requirements?
Dr. Stefan Blesse
Granzer Regulatory Consulting & Services
Picture: Granzer Regulatory Consulting & Services